8-K: Inspire Medical Systems Beats Q3, Boosts FY25 EPS Outlook

Inspire Medical Systems reported strong third-quarter 2025 financial results, with revenue up 10% and a significant increase in full-year diluted net income per share guidance, driven by the successful Inspire V system transition.

Summary

• Generated $224.5 million in revenue for Q3 2025, a 10% increase year-over-year.
• Achieved a gross margin of 85.8% in Q3 2025, up from 84.1% in Q3 2024.
• Reported net income of $9.9 million and diluted net income per share of $0.34 for Q3 2025.
• Adjusted diluted earnings per share was $0.38 for Q3 2025.
• Operating cash flow for Q3 2025 was $68.5 million, bringing the year-to-date total to $64.5 million.
• Completed $50 million in share repurchases during the third quarter.
• Reaffirmed full-year 2025 revenue guidance of $900 million to $910 million.
• Increased full-year 2025 diluted net income per share guidance to $0.90-$1.00, up from $0.40-$0.50.
• The Inspire V system launch is progressing well, with over 75% of centers ready to transition, demonstrating a 20% reduction in surgical procedure time and significant reductions in disease severity.

Sentiment

Score: 8

Explanation: The company reported strong revenue growth and significantly raised its full-year EPS guidance, indicating robust operational performance and positive future expectations despite a year-over-year decline in Q3 net income. The successful launch of the Inspire V system and strategic investments further bolster a positive outlook.

Positives

• Third-quarter 2025 revenue increased 10% year-over-year to $224.5 million.
• Gross margin improved to 85.8% in Q3 2025 from 84.1% in Q3 2024, driven by higher sales volume and Inspire V sales mix.
• Full-year 2025 diluted net income per share guidance was significantly raised to $0.90-$1.00, from previous guidance of $0.40-$0.50.
• Operating cash flow was strong at $68.5 million for Q3 2025, contributing to $64.5 million year-to-date.
• Completed $50 million in share repurchases during the third quarter, indicating confidence in the company's value.
• The Inspire V system shows enhanced performance, including a 20% reduction in surgical procedure time and clinically relevant reductions in disease severity, with 100% successful device implants in studies.
• Over 75% of U.S. centers are ready to transition to the new Inspire V system, indicating strong adoption.
• International revenue grew 37% year-over-year to $10.1 million in Q3 2025.

Negatives

• Net income for Q3 2025 decreased to $9.9 million from $18.5 million in Q3 2024.
• Diluted net income per share for Q3 2025 decreased to $0.34 from $0.60 in Q3 2024.
• Operating income for Q3 2025 decreased to $9.6 million from $14.3 million in Q3 2024.
• Operating expenses increased 17% year-over-year to $183.1 million in Q3 2025, primarily due to patient marketing and general corporate costs.
• Cash, cash equivalents, and investments decreased to $410.9 million as of September 30, 2025, from $516.5 million on December 31, 2024.

Risks

• History of operating losses and dependency on Inspire therapy for revenues.
• Commercial success and market acceptance of Inspire therapy.
• Ability to achieve and maintain adequate levels of coverage or reimbursement for Inspire therapy.
• Competition from other companies, technologies, and pharmaceuticals, including the potential impact of glucagon-like peptide 1 (GLP-1) class of drugs on demand.
• Involvement in current or future legal disputes or regulatory proceedings.
• Ability to expand indications and develop and commercialize additional products and enhancements.
• Challenges experienced by patients in obtaining prior authorization.
• Dependence on third-party suppliers, contract manufacturers, and shipping carriers.
• Risks associated with international operations and managing growth.
• Ability to hire and retain senior management and other highly qualified personnel.
• Risk of product liability claims and ability to address quality issues.
• Risks related to information technology and cybersecurity.
• Effect of delays in commercializing or obtaining regulatory approvals.

Future Outlook

The company reaffirmed its full-year 2025 revenue guidance of $900 million to $910 million and maintained its gross margin guidance of 84% to 86%. Diluted net income per share guidance for the full year 2025 was significantly increased to $0.90 to $1.00, up from the previous range of $0.40 to $0.50. Management is focused on the successful transition to the Inspire V system, execution, disciplined investments, and cost management. Future innovations include the development of Inspire VI and VII for auto-activation and auto-titration, and the PREDICTOR study to potentially replace DISE for patient screening.

Management Comments

• "The Inspire team had a very productive third quarter focusing on the transition to the Inspire V system while delivering very strong results globally."
• "At recent industry meetings, we presented clinical evidence demonstrating that the Inspire V system offers enhanced performance, building on the strong foundation established by our legacy systems."
• "Patient safety is paramount, and with our Inspire V study in Singapore of 44 patients and the Limited-Market-Release study of over 100 patients in the United States, 100% of patients had a successful device implant."
• "Device performance was equally impressive starting with a 20% reduction in surgical procedure time, and statistically significant and clinically relevant reductions in disease severity."
• "Recent field experience with the Inspire V system is generating very positive feedback from clinicians, and the team is making excellent progress with the U.S. launch with over 75% of centers ready to transition to Inspire V."
• "We remain laser-focused on execution and with our strong performance and disciplined investments and cost management, we are reaffirming our full year revenue guidance of $900 to $910 million and increasing our diluted net income per share guidance to $0.90 to $1.00, up from $0.40 to $0.50 previously."
• "I am very proud of how our team is executing and I look forward to a strong finish to the year."

Industry Context

Inspire Medical Systems operates in the growing medical technology market for obstructive sleep apnea (OSA), a condition affecting millions globally. The company positions its Inspire therapy as an innovative, minimally invasive alternative to traditional treatments like CPAP, which suffers from low patient compliance (35-65%), and invasive surgeries with variable success rates (30-60%). The company's focus on continuous product innovation, such as the Inspire V system and future iterations, and digital health platforms like SleepSync, aligns with broader industry trends towards advanced, patient-centric solutions and remote patient management. The acknowledgment of potential impact from GLP-1 class drugs highlights the dynamic competitive landscape, where pharmaceutical advancements could influence demand for device-based therapies.

Comparison to Industry Standards

• No specific comparable companies, projects, or results are detailed in the filing for a direct assessment against global benchmarks. The company primarily focuses on its own historical performance, market penetration, and the clinical efficacy of its proprietary Inspire therapy compared to conventional OSA treatments like CPAP and traditional surgeries.

Legal Proceedings

• Incurred $1.3 million in litigation-related legal expenses in Q3 2025.
• These expenses are related to a civil investigative demand from the Department of Justice.
• Also related to patent infringement suits filed by Inspire against Nyxoah S.A. and its subsidiary, and a patent infringement suit brought against Inspire by Nyxoah.

Stakeholder Impact

• Shareholders: Positive impact from strong revenue growth, increased full-year EPS guidance, and a $50 million share repurchase program, potentially leading to increased share value.
• Patients: Enhanced safety and efficacy with the new Inspire V system, including reduced surgical time and improved therapy performance, leading to better treatment outcomes for obstructive sleep apnea.
• Clinicians/ENTs: Improved efficiency and patient flow through the Inspire V system's reduced procedure time and the SleepSync digital health platform, supporting increased capacity and confidence in delivering Inspire therapy.
• Employees: Continued growth and investment in R&D and market expansion suggest job stability and potential for development within an innovative company.
• Creditors/Suppliers: Stable financial performance and reaffirmed revenue guidance indicate a reliable business partner.

Next Steps

• Participate in various meetings with investors and analysts in November and December 2025.
• Complete the full transition to the Inspire V neurostimulation system in the U.S.
• Continue development of Inspire VI and VII for auto-activation and future auto-titration.
• Conduct the PREDICTOR study, intended to replace DISE for many patients with an office airway measurement.
• Expand market presence and facilitate international market expansion.
• Enhance the SleepSync Digital Health Platform with future remote patient programming and physician notifications.

Key Dates

Recommendation

Inspire Medical Systems has demonstrated robust financial performance with a 10% year-over-year revenue increase and a significant upward revision of its full-year diluted net income per share guidance. The successful rollout of the innovative Inspire V system, which offers improved patient outcomes and reduced procedure times, positions the company strongly in a large, underpenetrated market for obstructive sleep apnea. Strategic investments in R&D, digital health platforms, and international expansion, coupled with a share repurchase program, underscore a confident management outlook and strong growth trajectory. While Q3 net income saw a year-over-year decline, the overall outlook and operational advancements make it a compelling investment.

Keywords

Obstructive Sleep Apnea, OSA, Inspire Therapy, Neurostimulation, Medical Technology, Sleep Apnea Treatment, Inspire V, SleepSync, Financial Results, Earnings, Q3 2025, INSP, FDA Approved, Minimally Invasive